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Abstract
Background: Tribendimidine is an anthelminthic drug with a broad spectrum of activity. In 2004 the drug was approved by
Chinese authorities for human use. The efficacy of tribendimidine against soil-transmitted helminths (Ascaris lumbricoides,
hookworm, and Trichuris trichiura) has been established, and new laboratory investigations point to activity against
cestodes and Strongyloides ratti.
Methodology/Principal Findings: In an open-label randomized trial, the safety and efficacy of a single oral dose of
albendazole or tribendimidine (both drugs administered at 200 mg for 5- to 14-year-old children, and 400 mg for
individuals $15 years) against soil-transmitted helminths, Strongyloides stercoralis, and Taenia spp. were assessed in a village
in Yunnan province, People’s Republic of China. The analysis was on a per-protocol basis and the trial is registered with
controlled-trials.com (number ISRCTN01779485). Both albendazole and tribendimidine were highly efficacious against A.
lumbricoides and, moderately, against hookworm. The efficacy against T. trichiura was low. Among 57 individuals who
received tribendimidine, the prevalence of S. stercoralis was reduced from 19.3% to 8.8% (observed cure rate 54.5%,
p=0.107), and that of Taenia spp. from 26.3% to 8.8% (observed cure rate 66.7%, p=0.014). Similar prevalence reductions
were noted among the 66 albendazole recipients. Taking into account ‘‘new’’ infections discovered at treatment evaluation,
which were most likely missed pre-treatment due to the lack of sensitivity of available diagnostic approaches, the difference
between the drug-specific net Taenia spp. cure rates was highly significant in favor of tribendimidine (p=0.001). No
significant adverse events of either drug were observed.
Conclusions/Significance: Our results suggest that single-dose oral tribendimidine can be employed in settings with
extensive intestinal polyparasitism, and its efficacy against A. lumbricoides and hookworm was confirmed. The promising
results obtained with tribendimidine against S. stercoralis and Taenia spp. warrant further investigations. In a next step,
multiple-dose schedules should be evaluated.
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Introduction
There is a growing awareness of the intolerable burden due to the
so-called neglected tropical diseases [1]. Hence, new initiatives are
underway for their control [2]. For helminth infections, the mainstay
of control in high-burden areas rests on regular administration of
anthelminthic drugs [1–5]. However, only a handful of drugs that
have been developed many years ago are available [6], and there is
considerable concern that resistance might develop, e.g., following
repeated exposure of helminths to sub-curative doses. Reduced
efficacy of common anthelminthic drugs is a major problem in
veterinary medicine already, but for humans, it is of no clinical
relevance thus far [7]. Another issue is that in a world where
intestinal polyparasitism is common, yet neglected [8–12], and
frequently used treatment regimens are only effective against a
limited number of helminths [6], some species which are not
effectively controlled by common drugs might increase in relative
frequency, e.g., Strongyloides stercoralis and Taenia spp.
High prevalences of soil-transmitted helminths (Ascaris lumbri-
coides, hookworm, and Trichuris trichiura) and, consequently, a high
www.plosntds.org 1 October 2008 | Volume 2 | Issue 10 | e322level of intestinal multiparasitism, have recently been described
from Nongyang, a settlement in Manguo administrative village,
located in southwest Yunnan province, People’s Republic of China
[13]. Whilst S. stercoralis is endemic in the People’s Republic of
China [14], the local epidemiology of this parasite is not well
understood. A prevalence of ,15% was found in Nongyang [15].
Taeniasis and infections with the larval stage of Taenia solium that
causes cysticercosis, have been documented throughout the
People’s Republic of China. Most infections occur in counties
inhabited by non-Han nationalities whose traditional diets include
the consumption of raw or undercooked meat [14,16]. However,
there is a paucity of epidemiologic data for taeniasis from the
People’s Republic of China, at least in the English literature [17].
In a recent cross-sectional survey, we found an egg-prevalence of
Taenia spp. of 3.5% among 3220 individuals in Eryuan county,
northwest Yunnan province [18]. In Nongyang, the prevalence of
Taenia spp. was 5.1% [13].
The benzimidazoles, i.e., albendazole and mebendazole, are the
most widely used drugs for the control of soil-transmitted
helminthiasis [1,19]. Both drugs have some effect against S.
stercoralis and Taenia spp., but triple doses are recommended to
achieve high cure rates [6,20]. The drug of choice for treating S.
stercoralis is ivermectin [21,22]. Praziquantel and niclosamide are
the recommended drugs against Taenia spp. [23–26]. Large-scale
administration of ivermectin is the cornerstone of control
programs targeting filarial infections, most notably onchocerciasis
[27]. However, Onchocerca volvulus is not endemic in the People’s
Republic of China. Additionally, ivermectin is highly efficacious
against A. lumbricoides, shows some activity against T. trichiura, but
fails to cure hookworm infections. Since hookworms are common
in the People’s Republic of China, ivermectin is not commonly
used for soil-transmitted helminth control in this country. These
issues might explain why ivermectin is registered for human use in
the People’s Republic of China, but not readily available.
Ivermectin, however, is produced at large scale for veterinary
medicine, the bulk of which is exported.
Tribendimidine is an anthelminthic drug that has been
registered in the People’s Republic of China for use in humans
[6,28]. Tribendimidine is a symmetrical diamidine derivative of
amidantel [28], its CAS registration number is 115103-15-6. Used
at the current standard dose of 200 mg for children aged 5 to 14
years, and 400 mg for individuals aged $15 years, tribendimidine
is safe and efficacious against A. lumbricoides, hookworm, and
Enterobius vermicularis [28]. It also shows some activity against T.
trichiura [29,30], cestodes [28], and some trematodes [31,32]. New
research revealed in vitro and in vivo activity of tribendimidine
against Strongyloides ratti [33].
The objective of this study was to assess the safety and efficacy
of single-dose oral tribendimidine for treating intestinal helminth
infections in a rural setting where polyparasitism is common, with
a focus on the effects on S. stercoralis and Taenia spp. Comparison is
made with single-dose oral albendazole as half of the participants
were administered either drug. The primary outcome measures
were the reduction of the infection prevalence of intestinal
helminths, and the frequency and severity of adverse events.
The secondary outcome measure was the Kato-Katz-derived egg
count reduction of common soil-transmitted helminths. Multiple
stool samples were collected before and after drug administration
and examined by different diagnostic tools to enhance the
diagnostic sensitivity.
Materials and Methods
Study site and population
The study was carried out in Nanweng, a village in Menghai
county, Xishuangbanna prefecture, Yunnan province, People’s
Republic of China, from May to July 2007. Nanweng has 81
resident families and is situated on the slope of a mountain,
1650 m above sea level at 21.77 N latitude and 100.40 E
longitude. The village is exclusively inhabited by the Bulang ethnic
group. Its economic basis is provided by the surrounding tea
plantations and the more distant, partially irrigated rice and other
crop fields. Untreated tap water is delivered to every house but no
sanitation facilities are available in the entire village.
Field and laboratory procedures
The leader of the Menghai-based county Center for Disease
Control and Prevention (CDC) briefed the village authorities
about the study. Village leaders then informed the residents who
were all invited to participate. Over a 3-week period, 20–30
families were enrolled weekly, and household as well as individual
questionnaires that have been used before [15,18] were admin-
istered. Children below the age of 15 years were assisted by their
parents or legal guardians to answer the questions, and infants
younger than 2 years were excluded from the study. Participants
were asked to provide a large stool sample in pre-labeled collection
containers. Filled containers were collected daily and exchanged
by empty ones with the goal to obtain 3 stool samples per
participant. The evaluation of the treatment efficacy commenced
2 weeks post-treatment and followed the same field procedures.
Stool samples were collected over a 2-week period, again aiming to
obtain 3 samples per study participant.
Stool samples were collected in the village between 07:00 and
09:00 a.m., transferred to the laboratory in Menghai city, and
processed within a maximum of 6 hours of receipt. First, ,10 g of
stool were placed on a gauze which was embedded on a wire mesh
in a glass funnel equipped with a sealable rubber tube, the so-
called Baermann device [33]. The funnel was then filled with de-
ionized water and illuminated from below with an incandescent
bulb. Second, for the Koga agar plate test [34], ,2 g of stool were
Author Summary
More than a billion people are infected with intestinal
worms and, in the developing world, many individuals
harbor several kinds of worms concurrently. There are only
a handful of drugs available for treatment, and drug
efficacy varies according to the worm species. We
compared the efficacy of a single oral dose of tribendimi-
dine, a new broad-spectrum worm drug from China, with
the standard drug albendazole for the treatment of
hookworm, large roundworm (Ascaris lumbricoides), whip-
worm (Trichuris trichiura) and, for the first time, Strongy-
loides stercoralis and tapeworm (Taenia spp.). Our single-
blind randomized trial was conducted in a village in
Yunnan province, southwest China. Both drugs showed
high efficacy against A. lumbricoides and a moderate
efficacy against hookworm. Among 57 tribendimidine
recipients, the prevalence of S. stercoralis was reduced
from 19.3% to 8.8%, and that of Taenia spp. from 26.3% to
8.8%. Similar prevalence reductions were noted among the
66 albendazole recipients. Taking into account additional
infections only discovered at treatment evaluation, the
difference between the drug-specific Taenia spp. net cure
rates was highly significant in favor of tribendimidine. In
view of our promising results, multiple-dose schedules
with tribendimidine against S. stercoralis and Taenia spp.
should be evaluated next.
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nutrient agar. Third, a single 41.7 mg Kato-Katz thick smear [35]
was prepared on a microscope slide and helminth eggs were
enumerated after a clearing time of 30–60 min.
The lowest 45 ml of the liquid in the Baermann funnel were
drained after2 h,centrifuged,andthesedimentwasexaminedforS.
stercoralis larvae at low magnification (406). Koga agar plates were
inspected for helminth larvae at similar magnification after a 2-day
incubation period at 28uC in a humid chamber. Subsequently, all
plates were rinsed with 12 ml sodium acetate–acetic acid–formaline
(SAF) solution [36], gently scraped, and the eluent was centrifuged.
The sediment was examined for helminth larvae, i.e., S. stercoralis
and hookworms. Helminth larvae were differentiated based on
established anatomical criteria, i.e., considering the buccal cavity
and genital primordium of first-stage (L1) S. stercoralis larvae (buccal
cavity: short; genital primordium: prominent), and the tip of the tail
of third-stage (L3) S. stercoralis larvae (tip of the tail: cut). Samples
were considered positive if larvae were detected at any stage and by
any test. Helminth eggs in the Baermann and Koga sediment were
also noted.
Randomization and drug administration
Study participants who had submitted at least 1 stool sample
were listed according to their identification number in ascending
order. Subsequently, a random sequence of 0’s and 1’s was
generated in Excel (Microsoft Corp.) by the study coordinator, and
aligned with the list of eligible study participants. Individuals
matched with a ‘‘0’’ were assigned albendazole, whereas those
with a ‘‘1’’ were assigned tribendimidine. Albendazole and
tribendimidine were purchased from Shanxi Hanwang Medicine
Co. Ltd. (Han Zhong, People’s Republic of China) and Shandong
Xinhua Pharmaceutical Co. Ltd. (Zibo, People’s Republic of
China), respectively. Drugs were administered as single 200 mg
oral dose for children aged 5 to 14 years, and 400 mg for
individuals $15 years of age. Drugs at the appropriate dosage
according to participants’ age were packed in identical envelopes
labeled with the participant’s name only. Hence, our study was an
open-label trial, i.e., participants did not know which drug they
received. Participants were asked to avoid alcohol consumption on
the day of drug administration. After dinner time, teams of
fieldworkers visited the village, met the participants at home and
asked them about signs of acute or chronic illness, and alcohol
consumption. Women aged $14 years were asked about
pregnancy. Drugs were handed out together with fresh bottled
water to healthy, non-drunk and non-pregnant participants, and
drug intake was observed. Those treated were asked to report any
potential drug-related signs or symptoms including sleeping
troubles to the accompanying medical doctor.
Ethical considerations and end-of-study treatment
The study was approved by the institutional research commis-
sion of the Swiss Tropical Institute (Basel, Switzerland). Ethical
clearance was obtained from the Ethics Committee of Basel
(EKBB), Switzerland (reference no. 149/07) and the Ethics
Committee of the National Institute of Parasitic Diseases, Chinese
Center for Disease Control and Prevention (Shanghai, People’s
Republic of China). The trial is registered with controlled-
trials.com under the registration number ISRCTN01779485.
The study procedures, potential risks, and benefits were explained
to the village leaders. After their consent to perform the study, field
workers visited the homes of the selected families where detailed
information was provided to all potential participants, and
questions were answered. Emphasis was placed on voluntary
participation and the option to quit the study at any moment
without further obligation. Written confirmation that full infor-
mation had been provided and individual participation was
voluntary (informed consent) was obtained from the head of each
participating household or a literary substitute (adult child or
relative), and this procedure was approved by the above-
mentioned ethical committees.
A single 200 mg (for children aged 5 to 14 years), or 400 mg
(individuals aged $15 years) oral dose of albendazole was offered
to those participants who were not eligible for randomization
because they had failed to provide any stool sample. The
assessment of their health status and the treatment procedures
followed the same protocol as for study participants, but the
treatment outcome was not assessed.
Locally-used remedies for Taenia spp. infection and ivermectin
for treating S. stercoralis at the standard dose (200 mg/kg) were
provided at the end-of-study follow-up. Finally, albendazole was
provided to the village authorities for later distribution to
untreated inhabitants and participants who still harbored active
infections.
Data management and statistical analysis
The target sample size was 130 individuals, based on the
following assumptions: Prevalence of S. stercoralis: 20%; efficacy of
tribendimidine and albendazole against S. stercoralis: 85% (similar
to ivermectin at standard dosage [37]) and 0%, respectively, with a
confidence level of 95% and a power of 80%.
The questionnaire data were double-entered and cross-checked
in EpiData version 3.1 (EpiData Association; Odense, Denmark).
The laboratory data were examined for internal consistency, and
merged with the questionnaire data. Statistical analysis was done
with STATA version 9.2 (StataCorp; College Station, USA). Our
final study cohort consisted of individuals aged $5 years who had
submitted at least 2 stool samples at baseline, did not suffer from
any chronic or acute illness, had not drunk alcohol on the day of
drug administration, for women were not pregnant, had taken the
randomly assigned drug, and had again at least 2 stool samples
examined at the end-of-study survey. Thus, statistical analyses only
considered treated individuals with complete diagnostic data
records, stratified by drug (see Figure 1, end points of the right
arm). Multiple stool readings at baseline and follow-up were
required in order to boost diagnostic sensitivity [13,15].
The infection status was determined based on the pooled results
from the different diagnostic methods (i.e., soil-transmitted
helminths and Taenia spp.: all tests; S. stercoralis: Baermann and
Koga agar plate tests). Pearson’s x
2-test and Fisher’s exact test, as
appropriate, were used to assess the association between infection
and demographic variables. Treatment outcomes by drug and the
differences between albendazole and tribendimidine were ex-
plored by calculating drug-specific prevalence reductions, and
analyzing the difference between the observed cure rates (2-sample
test of proportions). The infection intensity for the common soil-
transmitted helminths was determined based on the quantitative
Kato-Katz thick smear readings, multiplied by a factor of 24.
Infection intensities for individual study participants were obtained
by calculating the arithmetic mean of the available egg counts.
The arithmetic mean of the averaged egg counts among the
infected yielded a summery measure of infection intensity among
the infected population. The individual infection intensities were
subsequently stratified according to the classification proposed by
the World Health Organization (WHO) [38]. The effects of
albendazole and tribendimidine on the infection intensities in the
respective groups were analyzed using a paired t-test, and drug-
specific infection intensity reductions were compared by a 2-
sample test of proportions.
Tribendimidine against Intestinal Helminths
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Participation
We counted 294 family members, aged above 2 years, in the 81
resident families. Another 60 individuals were recorded in the
village registry but they had either left the village, were younger
than 2 years, or refused to answer the questionnaire. Figure 1
shows that 106 (36%) of the eligible participants provided none
(n=57), or only a single (n=49) stool sample of sufficient quantity
to perform all diagnostic tests. The remaining 188 individuals
(64%) were 5 to 87-year-old and among them, 17 could not be
treated due to pregnancy (n=8), ill health (n=5) or other reasons
(n=4). The randomization of the 171 participants with complete
parasitological baseline data who were eligible for treatment
resulted in equal-sized groups for single-dose oral tribendimidine
or albendazole administration, but stool sample submission at
baseline and actual treatment rates were somewhat lower among
tribendimidine recipients.
Of the 91 participants treated with albendazole, 2 to 3
sufficiently large stool samples were available from 66 individuals
(73%) at the end-of-study follow-up. A similar stool sample
submission rate was observed for the 80 tribendimidine recipients
(71%). The final cohort consisted of 123 individuals who received
either albendazole (n=66) or tribendimidine (n=57), and
submitted at least 4 (2 pre- plus 2 post-treatment) sufficiently
large stool samples to carry out the full range of diagnostic tests.
While drop-out rates were similar for males and females (42.2%
versus 41.5%), full participation ranged from 21% for 10 to 14-
year-olds to 58% for those aged $40 years (data not shown).
Helminth infections at baseline
Considering the joint results of the 2 to 3 Kato-Katz, Koga agar
plate and Baermann tests, our final cohort showed high
prevalences of T. trichiura (87.8%), hookworm (74.8%), and A.
lumbricoides (72.4%). The prevalences of Taenia spp. and S. stercoralis
were 26.0% and 17.9%, respectively.
Table 1 shows that Taenia spp. infections were significantly more
prevalent among males (33.9%) than females (18.0%, x
2=4.01,
degrees of freedom (df)=1, p=0.045) and increased with age,
albeit not significantly (p=0.163). An increase with age was also
noted in the prevalence of S. stercoralis infections. No S. stercoralis
were diagnosed among pre-school children and students as
opposed to farmers (p=0.121); Taenia spp. was also more common
among farmers (27.3%) than pre-school children and students
(8.3%, p=0.292). Illiterates had a lower A. lumbricoides prevalence
than those with formal education (50.0% vs. 79.2%, x
2=9.32,
df=1, p=0.002), reflecting the generally lower prevalence among
older age groups. Table 1 also summarizes the infection intensities
for the common soil-transmitted helminths according to the Kato-
Katz results. While most hookworm and T. trichiura infections were
of light intensity, a considerable number of moderate and a few
heavy infections were noted for A. lumbricoides.
Efficacy of tribendimidine and albendazole
As detailed in Table 2, single-dose oral albendazole and
tribendimidine significantly reduced the prevalence of A. lumbri-
coides (albendazole: from 75.8% to 0; tribendimidine: from 68.4%
to 5.3%; both p,0.001), and hookworm (albendazole: from 69.7%
to 21.2%; tribendimidine: from 80.7% to 38.6%; both p,0.001).
Figure 1. Participation and stool sample submission compliance in a community-based open label efficacy study involving
repeated stool sample collection and anthelminthic treatment by either albendazole or tribendimidine; Nanweng village, Yunnan
province, People’s Republic of China.
doi:10.1371/journal.pntd.0000322.g001
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www.plosntds.org 6 October 2008 | Volume 2 | Issue 10 | e322Whilst the difference between the drug-specific cure rates against
A. lumbricoides showed borderline significance in favor of albenda-
zole, there was no difference in the efficacy of the two drugs
against hookworm. Although neither albendazole nor tribendimi-
dine resulted in a significant reduction in the prevalence of T.
trichiura, single-dose oral albendazole was significantly more
efficacious than tribendimidine in curing T. trichiura (p=0.014).
Single-dose albendazole and tribendimidine significantly reduced
the arithmetic mean egg counts among those who were infected at
baseline (all p,0.05) except for tribendimidine administered to
individuals with T. trichiura (p=0.136). Both drugs decreased the
mean egg counts of A. lumbricoides and hookworm to a similar
extent, but mean T. trichiura egg counts declined significantly more
following albendazole than tribendimidine treatment (p=0.005).
Single-dose albendazole and tribendimidine resulted in preva-
lence reductions of S. stercoralis of 6.1% and 10.5%, respectively,
which was not statistically significant (both p.0.05). The
prevalence of Taenia spp. was reduced from 25.8% to 10.6% after
albendazole administration (p=0.024), whilst among the tribendi-
midine recipients, the prevalence was lowered from 26.3% to
8.8% (p=0.014). Table 2 also shows that after administration of
albendazole, S. stercoralis larvae could still be found among 7 of the
previously 11 infected individuals (observed cure rate: 36.4%).
Among those treated with tribendimidine, 6 out of 11 individuals
were larvae-free (observed cure rate: 54.5%; difference: 18.1%,
p=0.394). The baseline Taenia spp. prevalence of 25.8% and
26.3% among those given albendazole and tribendimidine was
reduced by 58.8% and 66.7%, respectively (difference: 7.9%,
p=0.645).
Taking into account S. stercoralis and Taenia spp. infections that
had only been recognized at treatment evaluation (these infections
were most likely missed pre-treatment due to the lack of diagnostic
sensitivity of the available tests), the efficacy of the drugs was lower
(Table 3). In both treatment groups, S. stercoralis was diagnosed in 2
individuals previously declared uninfected. Hence, the net cure
rate was 18.2% for albendazole and 36.4% for tribendimidine
recipients (difference: 18.2%, p=0.338). The number of ‘‘new’’
Taenia spp. infections in the albendazole group diagnosed during
follow-up equaled the number of recoveries (n=10), resulting in a
zero overall cure rate. Among tribendimidine recipients, only 2
additional Taenia spp. infections were found; the prevalence
reduction showed borderline significance (214.0%, p=0.058).
The net cure rate of Taenia spp. in the tribendimidine recipients
was 53.3%, significantly different from the albendazole group
(difference: 53.3%, p=0.001).
Adverse events
No adverse events were mentioned by participants treated with
single-dose oral albendazole. In the tribendimidine group, an 87-
year-old woman reported mild sleeping disorders, headache,
dizziness, and gastrointestinal symptoms, including a single
episode of vomiting. This subject had a light infection with T.
trichiura and hookworm at baseline. Upon treatment evaluation,
the participant did not submit any further stool samples, and
hence was excluded from the final cohort.
Discussion
To our knowledge, this is the first investigation assessing the
safety and efficacy of single-dose tribendimidine for treating S.
stercoralis and Taenia spp. infections, and the first clinically-
monitored use of tribendimidine in a setting with high rates of
intestinal multiparasitism. Indeed, infections with one of the three
main soil-transmitted helminths were found in 72.4–87.8% of the
study participants, and only 4 of the 123 individuals in our final
cohort (3.3%) harbored none of these helminths. The prevalence
of S. stercoralis and Taenia spp. at baseline was 17.9% and 26.0%,
respectively. Our study was an open-label trial, comparing a single
oral dose of albendazole with that of tribendimidine, with both
drugs administered at either 200 mg or 400 mg according to
participants’ age.
The final study cohort comprised less than 50% of those initially
contacted. Whilst the cohort had a similar sex distribution than the
total population of Nanweng village, it was considerably biased
toward older age groups. We screened multiple stool samples for
intestinal helminths and randomly assigned the participants to
either albendazole or tribendimidine. Treatment outcome was
assessed 2 to 4 weeks after dosing using multiple stool samples and
a diversity of diagnostic approaches. The prevalence of S. stercoralis
was not significantly reduced by either albendazole or tribendi-
Table 3. Prevalence and net cure rates of S. stercoralis and Taenia spp. taking into account ‘‘new’’ infections discovered at follow-
up among previously ‘‘negative’’ participants.
S. stercoralis Taenia spp.
Albendazole Tribendimidine Albendazole Tribendimidine
n Prev. (%) n Prev. (%) n Prev. (%) n Prev. (%)
Total samples 66 100 57 100 66 100 57 100
Positive before treatment 11 16.7/100 11 19.3/100 17 25.8/100 15 26.3/100
Still positive after treatment 7 10.6/63.6 5 8.8/45.5 7 10.6/41.2 5 8.8/33.3
‘‘New’’ positive after treatment 2 3.0/18.2 2 3.5/18.2 10 15.2/58.8 2 3.5/13.3
Total positive after treatment 9 13.6/81.8 7 12.3/63.6 17 25.8/100 7 12.3/46.7
Net prevalence reduction 3.1 (29.1–15.3)
a p=0.619 7.0 (26.3–20.3)
a p=0.306 0.0(214.9–14.9)
a p=1.000 14.0 (20.3–28.3)
a p=0.058
Net cured/net cure rate 2 18.2 4 36.4 0 0 8 53.3
Difference between
drug-specific net cure rates
18.2 (218.2, 54.6)
a p=0.338 53.3 (28.1, 78.5)
a p=0.001
Effect of single-dose oral albendazole or tribendimidine among 123 study participants from Nanweng village, Yunnan province, People’s Republic of China who
submitted at least 2 stool samples before and again after treatment (Prev., prevalence).
a95% confidence interval.
doi:10.1371/journal.pntd.0000322.t003
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Among individuals infected with Taenia spp. at baseline, the
observed cure rates of 58.8% for albendazole and 66.7% for
tribendimidine showed statistical significance (both p,0.05).
During follow-up, however, additional infections were found,
mainly Taenia spp. among those who had received albendazole,
and the difference between the drug-specific overall cure rates was
53.3% (p=0.001). The observed cestocidal effect of tribendimi-
dine, for the time being, should rather be regarded as an indication
of a possible activity than as a proof-of-concept. This is due to the
obvious diagnostic challenges encountered in field-based clinical
studies on large cestodes.
In the current trial, albendazole generally performed slightly
better than tribendimidine in curing common soil-transmitted
helminth infections. The most notable difference was seen with T.
trichiura, confirming earlier observations that single-dose albenda-
zole is somewhat more efficacious than single-dose tribendimidine
against this nematode [6]. The observed cure rates against
hookworm and T. trichiura following single-dose albendazole are
rather low compared to the results of a recent meta-analysis of this
and other WHO-recommended anthelminthics commonly used
against common soil-transmitted helminth infections [39]. We
speculate that this observation is rather reflecting the rigorous
diagnostic approach employed than an unusually low susceptibility
of local hookworm and T. trichiura to albendazole. For example,
hookworm infections could not only be detected by the widely
used Kato-Katz technique, but also by the Koga agar plate
method. However, the low cure rates observed in this study should
also be seen as a warning sign and call for monitoring of drug
efficacy and the potential emergence of drug resistance [38].
The inclusion of only 123 individuals who met our sample
submission requirements into the final study cohort reduced the
reported compliance rate but increased the reliability of the results
due to the increased overall sensitivity of the employed diagnostic
methods [15]. Indeed, a lower prevalence was found among those
175 participants who had at least 1 stool sample analyzed, but the
drug-specific efficacies were similar (data not shown).
The discovery of notable numbers of infections among those
who were deemed negative before treatment can be explained by
at least 2 mechanisms, or a combination thereof. First, it is
conceivable that the baseline evaluation fell within the prepatent
period of recent infections. Second, it is well known that
parasitological diagnosis of both S. stercoralis [40] and Taenia spp.
[25,41] lacks sensitivity. For S. stercoralis, the main remedy for this
challenge is screening of multiple stool specimens [21], whilst for
Taenia spp., sensitive coproantigen enzyme-linked immunosorbent
assay (ELISA) tests provide valuable alternatives [23,25,26,41].
The current diagnostic ‘gold’ standard to confirm treatment
success in taeniasis is the recovery of the tapeworm scolex.
Alternatively, the absence of proglottids from stools and
underwear over a period of 3 months also provides solid proof
of cure. However, such extensive observation is usually only
feasible in hospital settings. Re-infection after treatment can
almost certainly be excluded for Taenia spp., and it is rather
unlikely for S. stercoralis. We speculate that in our study, the limited
sensitivity of the diagnostic tools was more significant since the 3 to
5-week period between baseline and follow-up investigation is
rather short for any notable level of re-infections.
We are confident that our results are valid despite the imperfect
sensitivity of the employed diagnostic tests, not least due to our
rigorous sampling effort. This assumption is supported by the
following observations. For S. stercoralis, the numbers of ‘‘new’’
infections at follow-up was similar in both treatment groups (both
n=2), thus reducing the observed cure rate but not affecting the
overall conclusion that both drugs exhibit some effect at the
employed dosage. A mathematical model [42] for the prediction of
‘‘true’’ prevalence further suggested an underestimation of the S.
stercoralis prevalence by the employed procedures within the range
actually observed in the present trial [15]. After a study involving
extensive stool sample collection and analysis by the Baermann
technique, Dreyer and co-workers [43] suggested that at least 4
stool samples need to be collected to accurately assess the S.
stercoralis infection status, and that only those with at least 2 positive
test results should be included in clinical drug trials. In our study,
we only included those individuals who had at least 2 stool
specimens examined with 2 different diagnostic approaches. Thus,
at least 4, and ideally 6, results were available to judge the
infection status of the participants both before and after drug
administration. Among the 22 S. stercoralis positives at baseline, 6,
6, 3, 5, 1 and 1 individuals had 1, 2, 3, 4, 5 and 6 positive test
results, respectively. The 10 arguably cured individuals had 1
(n=3), 2 (n=3), 3 (n=2) and 4 (n=2) positive baseline test results.
Our findings indicate that participants with only 1 or 2 positive
tests at baseline were not more likely to be considered cured at
treatment evaluation than those with multiple positive tests.
However, infections were still found in all participants with 5 or 6
positive tests at baseline. The four individuals who were only found
to be infected at treatment evaluation then had 1, 1, 2 and 3
positive test results. Finally, the observed activity of albendazole
against Taenia spp. among those who were found to be infected at
baseline has to be put into perspective with the high number of
‘‘newly’’ detected infections at treatment evaluation. Among
tribendimidine recipients, only few additional Taenia spp. infec-
tions were found, indeed indicating that single-dose tribendimi-
dine, but not albendazole, might have some effect against Taenia
spp.
Unfortunately, the eggs of T. saginata, T. solium, and T. asiatica
cannot be readily distinguished microscopically [23,25]. Hence,
we are not in a position to determine their relative frequency in
our study population. However, the reported and observed diets
suggest that the locally dominant species is T. solium or possibly T.
asiatica since Bulang favor raw pork over raw beef.
As a next step, the efficacy of multiple-dose tribendimidine
could be assessed as our results indicate some, albeit currently
unsatisfactory effect of this drug against S. stercoralis and Taenia spp.
In future studies with a focus on these 2 parasites rather than the
common soil-transmitted helminths, the reference drug should be
praziquantel or niclosamide for Taenia spp., and ivermectin for S.
stercoralis. Alternatively, triple-dose albendazole might be used as
reference treatment [20]. When further investigating the efficacy
of tribendimidine against large cestodes, including Taenia spp. in
humans, we propose to treat a small group of confirmed taeniasis
cases who agreed to submit multiple stool samples and observe
proglottids in their stools and underwear over extended time
periods.
Infections with A. lumbricoides and hookworm are the main
targets for single-dose mass chemotherapy using albendazole or
mebendazole. Discussions are underway in the People’s Republic
of China for the larger-scale use of tribendimidine. Efficacy of the
latter drug on other intestinal parasites would be of considerable
public health significance, which is explained by the geographic
overlap of different helminth infections, including S. stercoralis and
Taenia spp. Treatment of individuals with multiple species parasite
infections, including S. stercoralis and Taenia spp., is likely to occur.
Hence, there is a pressing need to determine the most efficacious
tribendimidine treatment regimen for S. stercoralis and Taenia spp.
since the exposure of the parasites to sub-curative doses
exacerbates the risk of resistance development. Therefore,
Tribendimidine against Intestinal Helminths
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assure timely detection of emerging resistance.
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